OBJECTIVE: This study assessed the effect of public health advisories issued between 2005 and 2007 by the U.S. Food and Drug Administration (FDA) on treatments of attention-deficit hyperactivity disorder (ADHD) and physician prescribing practices. METHODS: Data obtained from the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory physicians, were used to examine trends in office visits by children and adolescents (under age 18) during which ADHD was treated with Adderall, other psychostimulants, or atomoxetine. Segmented time series regressions were conducted to determine changes in use associated with three advisories issued between 2005 and 2007. RESULTS: In 2004, before the first FDA advisory, Adderall accounted for 36% of ADHD pharmacotherapy treatment visits. Other stimulants accounted for 46%, and atomoxetine accounted for 19%. Overall pharmacotherapy treatment rates were stable over the study period, but by 2008 the treatment visits accounted for by Adderall (that is, market share) declined to 24%, and the market share for atomoxetine declined to 8%. The market share for substitute therapies-clonidine, guanfacine, and bupropion-was stable over this period, ranging from 5% to 7%. Despite the declines in the use of Adderall and atomoxetine over the study period, results from the regression models suggest that the advisories did not have a statistically significant effect on ADHD medication prescribing. CONCLUSIONS: FDA advisories regarding potential cardiovascular and other risks of ADHD medications had little discernible incremental effect on the use of these medicines in this nationally representative ambulatory audit.
OBJECTIVE: This study assessed the effect of public health advisories issued between 2005 and 2007 by the U.S. Food and Drug Administration (FDA) on treatments of attention-deficit hyperactivity disorder (ADHD) and physician prescribing practices. METHODS: Data obtained from the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory physicians, were used to examine trends in office visits by children and adolescents (under age 18) during which ADHD was treated with Adderall, other psychostimulants, or atomoxetine. Segmented time series regressions were conducted to determine changes in use associated with three advisories issued between 2005 and 2007. RESULTS: In 2004, before the first FDA advisory, Adderall accounted for 36% of ADHD pharmacotherapy treatment visits. Other stimulants accounted for 46%, and atomoxetine accounted for 19%. Overall pharmacotherapy treatment rates were stable over the study period, but by 2008 the treatment visits accounted for by Adderall (that is, market share) declined to 24%, and the market share for atomoxetine declined to 8%. The market share for substitute therapies-clonidine, guanfacine, and bupropion-was stable over this period, ranging from 5% to 7%. Despite the declines in the use of Adderall and atomoxetine over the study period, results from the regression models suggest that the advisories did not have a statistically significant effect on ADHD medication prescribing. CONCLUSIONS: FDA advisories regarding potential cardiovascular and other risks of ADHD medications had little discernible incremental effect on the use of these medicines in this nationally representative ambulatory audit.
Authors: Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser Journal: Pediatrics Date: 2011-10-16 Impact factor: 7.124
Authors: William O Cooper; Laurel A Habel; Colin M Sox; K Arnold Chan; Patrick G Arbogast; T Craig Cheetham; Katherine T Murray; Virginia P Quinn; C Michael Stein; S Todd Callahan; Bruce H Fireman; Frank A Fish; Howard S Kirshner; Anne O'Duffy; Frederick A Connell; Wayne A Ray Journal: N Engl J Med Date: 2011-11-01 Impact factor: 91.245
Authors: Charles B Nemeroff; Amir Kalali; Martin B Keller; Dennis S Charney; Susan E Lenderts; Elisa F Cascade; Hugo Stephenson; Alan F Schatzberg Journal: Arch Gen Psychiatry Date: 2007-04
Authors: Tanya E Froehlich; Bruce P Lanphear; Jeffery N Epstein; William J Barbaresi; Slavica K Katusic; Robert S Kahn Journal: Arch Pediatr Adolesc Med Date: 2007-09
Authors: Victoria L Vetter; Josephine Elia; Christopher Erickson; Stuart Berger; Nathan Blum; Karen Uzark; Catherine L Webb Journal: Circulation Date: 2008-04-21 Impact factor: 29.690
Authors: Lian-Yu Chen; Rosa M Crum; Eric C Strain; G Caleb Alexander; Christopher Kaufmann; Ramin Mojtabai Journal: J Clin Psychiatry Date: 2016-03 Impact factor: 4.384
Authors: Nicola C Savill; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David Coghill Journal: CNS Drugs Date: 2015-02 Impact factor: 5.749
Authors: Stephen V Faraone; Catia Scassellati; Cristian Bonvicini; Samuele Cortese; Carlo Maj; Bernhard T Baune Journal: Transl Psychiatry Date: 2020-02-19 Impact factor: 6.222
Authors: Susanna N Visser; Melissa L Danielson; Rebecca H Bitsko; Joseph R Holbrook; Michael D Kogan; Reem M Ghandour; Ruth Perou; Stephen J Blumberg Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-11-21 Impact factor: 8.829
Authors: Vilawan Chirdkiatgumchai; Hong Xiao; Bridget K Fredstrom; Ryan E Adams; Jeff N Epstein; Samir S Shah; William B Brinkman; Robert S Kahn; Tanya E Froehlich Journal: Pediatrics Date: 2013-09-30 Impact factor: 7.124
Authors: Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas Journal: Front Hum Neurosci Date: 2022-09-26 Impact factor: 3.473